Artwork
iconShare
 
Manage episode 478867250 series 3380023
Content provided by Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

What do you do when most trials suggest benefit for an intervention, but then a new trial suggests harm? We thought steroids in pneumonia was a settled question, but REMAP-CAP had other plans!

We also review a new RCT for BP targets in patients with hypertension and diabetes, a new aldosterone synthase inhibitor for hypertension, and reduced dose apixaban for cancer-associated thrombosis.

Hydrocortisone for Severe CAP (REMAP-CAP)

Predicting Benefit of Corticosteroids in Pneumonia

Intensive BP Control in Patients with Diabetes (BPROAD)

Lorundrostat for Uncontrolled Hypertension (ADVANCE-HTN)

Reduced Dose Apixaban for Cancer Associated Thrombosis (API-CAT)

Music from Uppbeat (free for Creators!):

https://uppbeat.io/t/soundroll/dope

License code: NP8HLP5WKGKXFW2R

  continue reading

62 episodes